DALLAS and LONDON, Dec. 13 /PRNewswire/ -- U.S. Preventive Medicine(R), a company that is building the first network focused on prevention in the United States and internationally (http://www.USPreventiveMedicine.com), announced today it has signed a letter of intent with iHealth UK Ltd. to jointly develop three preventive medicine businesses in the United Kingdom. iHealth brings together leading clinicians, advanced modalities, electronic integration and a holistic perspective to support enhanced wellbeing through its health screening and assessment services.
As part of the agreement, iHealth will market preventive medicine services initially in the greater London area, wider UK and other international markets in collaboration with U.S. Preventive Medicine (USPM) by leveraging USPM's proprietary systems, operating procedures and branding and marketing materials.
In addition, iHealth will jointly develop and operate USPM's proprietary services and products in England, including The Prevention Plan(TM), a groundbreaking personalized wellness program delivered online to individuals. The Prevention Plan is primarily sold to employers to help manage future health costs. It helps individuals determine their top health risks and provides a step-by-step plan for improving and tracking their health. The agreement also enables iHealth to jointly develop and operate USPM's chronic disease management business in England.
"We are excited to provide practical solutions for preventive care and disease management to consumers in England through our agreement with iHealth," said Christopher Fey, Chairman and CEO of U.S. Preventive Medicine. "This expansion into Europe is the first step in USPM's plan to provide practical solutions at every point in the healthcare continuum both nationally and internationally."
"Our partnership with USPM gives us access to an even wider team of health care experts to share knowledge, experiences, new technologies, procedures and treatments and provide the best possible preventive health programs," said Stefan Wisbauer, Chief Executive Officer of iHealth. U.S. Preventive Medicine and iHealth expect to sign a definitive agreement in January, 2008.
About U.S. Preventive Medicine:
U.S. Preventive Medicine(R), a privately owned company, is building the first network in the United States and internationally focused on prevention. They offer employers, government agencies and consumers proprietary products that include The Prevention Plan(TM), a groundbreaking personalized wellness program delivered online to individuals; Experience Health 365(R), field-based chronic disease management programs customized for employers and government agencies to reduce healthcare costs; and The Centers for Preventive Medicine(R), which offer high-tech diagnostic screenings delivered to consumers in partnership with hospitals, health systems and other providers. For more information, please visit http://www.USPreventiveMedicine.com.
About iHealth UK Ltd.:
iHealth UK Ltd. is arguably the most advanced focused provider of preventive care in the UK, combining the full range of advanced diagnostics from all imaging modalities to genetics and consultant-led reviews in a fashion tailored to each client's key risk factors and concerns. For more information, please visit http://www.iHealthLtd.com.
This news release contains forward-looking statements, which may not accurately reflect our actual results of operations. Some of the information in this news release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements typically are identified by use of terms like "may," "will," "expect," "anticipate," "estimate," and similar words, although some forward-looking statements are expressed differently. The reader should be aware that our actual results could differ materially from those contained in the forward-looking statements due to a number of factors, including insufficient capital resources, inability to compete effectively, adverse economic conditions, unanticipated difficulties in product development and inability to gain market acceptance and market share.
|SOURCE U.S. Preventive Medicine|
Copyright©2007 PR Newswire.
All rights reserved